Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited Dividend Yield on January 15, 2025

Kazia Therapeutics Limited Dividend Yield is NA on January 15, 2025, a NA change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Kazia Therapeutics Limited 52-week high Dividend Yield is NA on None, which is NA below the current Dividend Yield.
Kazia Therapeutics Limited 52-week low Dividend Yield is NA on None, which is NA below the current Dividend Yield.
Kazia Therapeutics Limited average Dividend Yield for the last 52 weeks is NA.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years